Mobile Site ›

Clopidogrel Platelet Function Tests

Caveats and Controversies


Receive notification when new Hot Topics are published:

P2Y12 Antagonists2

Slide 16

December 2011

New P2Y12 antagonists have recently been introduced. Two years ago prasugrel was FDA approved and in July 2011, ticagrelor was FDA approved as well. Ticagrelor is the first direct antagonist, meaning that it does not require metabolism by the liver to become active as the prodrugs ticlopidine, clopidogrel and prasugrel do to form an active metabolite. Ticagrelor is also the first reversible P2Y12 antagonist. Other antagonists which can be given intravenously are now under investigation.

P2Y12 Antagonists2


Jump to section: